Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Nov 3:3:259-64.
doi: 10.2147/ppa.s3901.

Drospirenone/ethinyl estradiol 3 mg/20 mug (24/4 day regimen): hormonal contraceptive choices - use of a fourth-generation progestin

Gloria Bachmann  1 , Sharon Kopacz
Affiliations

Drospirenone/ethinyl estradiol 3 mg/20 mug (24/4 day regimen): hormonal contraceptive choices - use of a fourth-generation progestin

Gloria Bachmann et al. Patient Prefer Adherence. .

Abstract

The combined oral contraceptive pill (COC) consisting of drospirenone 3 mg/ethinyl estradiol 20 mug (3 mg DRSP/20 mug EE-24/4) supplies 24 days of pills with hormones followed by 4 days of hormone-free pills. This regimen is called the 24/4 regimen. The progesterone component of this oral contraceptive pill (OCP), drospirenone (DRSP), is a fourth-generation progestin that has potent progestogenic, antimineralocorticoid, and antiandrogenic activity, which are unique characteristics compared with the other progestogens contained in most of the other OCPs currently marketed. This formulation, in addition to being an effective long-term OCP, has the additional medical benefit of providing a good parallel treatment for premenstrual dysphoric disorder and moderate acne. The effectiveness of 3 mg DRSP/20 mug EE-24/4, its tolerability and safety, and its additional non-contraceptive benefits are discussed.

Keywords: acne vulgaris; antiandrogenic activity; antimineralocorticoid activity; contraception; drospirenone; premenstrual dysphoric disorder.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Structure of drospirenone and ethinyl estradiol.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Mosher WD, Martinex GM, Chandra A, et al. Use of contraception and use of family planning services in the United States: 1982–2002. Adv Data. 2004;350:1–36. - PubMed
    1. Fenton C, Wellington K, Moen MD, Robinson DM. Drospirenone/ethinylestradiol 3 mg/20 mcg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris. Drugs. 2007;67(12):1748–1765. - PubMed
    1. Bachmann G, Sulak PJ, Sampson-Landers C, et al. Efficacy and safety of a low dose 24 day combined oral contraceptive containing 20 mcg ethinylestradiol and 3 mg drospirenone. Contraception. 2004;70(3):191–198. - PubMed
    1. First MB, editor. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington (DC): American Psychiatric Press; 2000. Premenstrual dysphoric disorder; pp. 771–774.
    1. Steiner M, Born L. Diagnosis and treatment of premenstrual dysphoric disorder: An update. Int Clin Psychopharmacol. 2000;15(Suppl 3):S5–S17. - PubMed